Kura Oncology第四季度GAAP每股亏损$(0.22)优于预期$(0.65),销售额达$53.88M远超预期$8.50M

财报速递2025-02-27
Kura Oncology(NASDAQ:KURA)报告称,其季度每股亏损$(0.22),优于分析师一致预期的$(0.65),超出预期66.15%。相比去年同期每股亏损$(0.55),同比改善60%。公司报告季度销售额为$53.88M,远超分析师预期的$8.50M,增长533.92%。

以上内容来自Benzinga Earnings专栏,原文如下:

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.65) by 66.15 percent. This is a 60 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $53.88 million which beat the analyst consensus estimate of $8.50 million by 533.92 percent.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法